The GO and KEGG analyses highlighted enrichment terms predominantly associated with the extracellular matrix (ECM), coagulation, RAS, and endopeptidase
2024;209:A1084
The gap between trial and real-world tirzepatide vs semaglutide outcomes comes mostly from discontinuation and under-titration: only 25.9% of tirzepatide users reach 15 mg in practice, versus 83.5% of semaglutide users reaching 2.4 mg in the trial
Lin Q, Zhou Z, Luo W, Fang M, Li M, Li H
While beneficial for most patients, Semaglutide might also have side effects such as nausea, heartburn, headache, and more
Research on peptide capsules generally shows that tetrapeptides like epitalon fare poorly when taken orally without specialized delivery systems designed to protect against gastric breakdown